Flyrcado™ : A Breakthrough In Cardiac PET Imaging For...

agregó una foto Health

2025-09-27 08:28:34 - Translate -

Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease

In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...

0 Commentarios 0 Acciones 596 Views 0 Vista previa